Patient dies in Rocket gene therapy trial; Lilly’s $1B deal for a non-opioid pain biotech; A new dawn for psychedelics?; and more

Welcome back to Endpoints Weekly! The last week in May brought a lot of news, and it isn’t over yet. We’ve got reporters on the ground at the ASCO meeting in Chicago this weekend, so ...